Erlotinib Mechanism of Action in Non-Small Cell Lung Cancer (NSCLC)
Description
Erlotinib inhibits autophosphorylation of the epidermal growth factor receptor (EGFR) cytoplasmic domain, controlling constitutive signalling through the PI3K/AKT pathway in non-small cell lung cancer (NSCLC).
Acknowledgements
References
Khaddour K, Jonna S, Deneka A, Patel JD, Abazeed ME, Golemis E, Borghaei H, Boumber Y. Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies. Cancers. 2021; 13(13):3164. https://doi.org/10.3390/cancers13133164
Get started with this template for freeDon’t start from scratch.
Create professional scientific illustrations quickly and easily, even without any design expertise
- Get started with a huge library of editable icons and templates such as common biological pathways, anatomy, or genetics.
- Create figures that effectively communicate your research in half the time using our editable icons.
- Use our PDB tool to quickly generate and customize protein structures
.gif)
